Among other things, March is Women’s History Month, giving us an opportunity to acknowledge and appreciate the contributions women have made to society at large while enhancing their own lives.
One such influential woman Contemporary OB/GYN® would like to thank and celebrate is Editorial Advisory Board member Laura Riley, MD, who was recently awarded the Society for Maternal-Fetal Medicine’s (SMFM) Lifetime Achievement Award at SMFM’s 42nd Annual Pregnancy Meeting held January 31 to February 5, 2022. This award was created to recognize physicians who have made significant contributions to the field of maternal-fetal medicine.
We asked Riley’s fellow board members about the significance of this award and the impact Riley’s work has had on this field. Here’s what some of them had to say:
“Laura has been an important and influential leader, expert, mentor, and researcher in maternal-fetal medicine and [obstetrics-gynecology] her entire life,” said Christian Pettker, MD. “Her lifetime experience and achievement, and her stature and credibility were critical to disseminate accurate information, mobilize better resources and attention, and correct the major gaps and disenfranchisement affecting pregnant people affected and at risk for COVID-19. It is clear that, although this is a lifetime achievement award, her work is nowhere near complete.”
Sarah Kilpatrick, MD, added, “Dr Riley is a fantastic choice for the SMFM Lifetime Achievement Award. She has contributed across our field and within SMFM from mentor to presenter to organizer to leader.”
Again, we thank Riley for all her contributions to both maternal-fetal medicine and Contemporary OB/GYN®.
__
Mike Hennessy Jr
President and CEO, MJH Life Sciences®
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More